Form 4: Beyond Air board approves option repricing effective Nov 4, 2025
Rhea-AI Filing Summary
Beyond Air (XAIR) filed a Form 4 disclosing an option repricing for its CEO and Chairman, Steven A. Lisi. The Board approved an adjustment effective November 4, 2025, reducing the exercise price of multiple existing stock option grants to $1.95 per share, which the filing states was the closing price on November 3, 2025. All other terms of the options remain unchanged.
The Form 4 lists several grant lots that were modified, including blocks such as 47,500 and 40,000 options that previously carried higher exercise prices like $10.80 and $5.892 per share. The options were issued under the company’s Amended and Restated 2013 Equity Incentive Plan and continue to vest per their original schedules, contingent on continued service.
Positive
- None.
Negative
- None.
Insights
Administrative repricing to $1.95; terms and vesting unchanged.
The board-approved adjustment on November 4, 2025 reduces exercise prices on multiple outstanding options to $1.95, matching the stated prior-day close. The filing lists several grants that were moved from higher strikes (e.g., $10.80, $5.892) to the new level.
Per the disclosure, all other terms remain the same and vesting continues under the 2013 Equity Incentive Plan and prior award agreements, dependent on continued service. This is a compensation administration event; cash-flow effects depend on future exercises and are not indicated in the excerpt.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Options (Right to buy) | 47,500 | $0.00 | -- |
| Grant/Award | Stock Options (Right to buy) | 47,500 | $0.00 | -- |
| Disposition | Stock Options (Right to buy) | 40,000 | $0.00 | -- |
| Grant/Award | Stock Options (Right to buy) | 40,000 | $0.00 | -- |
| Disposition | Stock Options (Right to buy) | 14,000 | $0.00 | -- |
| Grant/Award | Stock Options (Right to buy) | 14,000 | $0.00 | -- |
| Disposition | Stock Options (Right to buy) | 10,000 | $0.00 | -- |
| Grant/Award | Stock Options (Right to buy) | 10,000 | $0.00 | -- |
| Disposition | Stock Options (Right to buy) | 3,500 | $0.00 | -- |
| Grant/Award | Stock Options (Right to buy) | 3,500 | $0.00 | -- |
| Disposition | Stock Options (Right to buy) | 12,500 | $0.00 | -- |
| Grant/Award | Stock Options (Right to buy) | 12,500 | $0.00 | -- |
| Disposition | Stock Options (Right to buy) | 20,000 | $0.00 | -- |
| Grant/Award | Stock Options (Right to buy) | 20,000 | $0.00 | -- |
| Disposition | Stock Options (Right to buy) | 47,500 | $0.00 | -- |
| Grant/Award | Stock Options (Right to buy) | 47,500 | $0.00 | -- |
Footnotes (1)
- On November 4, 2025, the Issuer's Board of Directors approved an option repricing, effective as of November 4, 2025, reducing the exercise price to $1.95 per share, the closing price of the Issuer's common stock on November 3, 2025. All of the other terms of the options remain unchanged. This stock option award was issued pursuant to the Company's Amended and Restated 2013 Equity Incentive Plan, as amended, (the "|2013 Plan") and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form-4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
